Another study has shown that Gal-3 inhibitor DAVANAT® reduces cholangitis induced by Novosphingobium aromaticivorans [138] and DSS-induced colitis [44] by reducing the activation of NLRP3 inflammasome and expression of IL-1β in macrophages. This evidence concerns the gene IL1B and colitis.